• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Cannabis » Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

Drew Hendricks by Drew Hendricks
April 26, 2019
in Cannabis
2 min read
29
0
Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

TEL AVIV, Israel, April 3, 2017, CNBX, /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma).

The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company’s cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells.

These results pave the way for a possible antitumor treatment which the company will further examine. Moreover, the differential efficacy of different cannabinoids emphasizes the need for personalized diagnostics –  and the data obtained serves this purpose.

Itamar Borochov, CEO of Cannabics Pharmaceuticals said, “The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine”.

About Cannabics Pharmaceuticals Inc.

Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized anti-cancer and palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K/A  Report filed on March 15, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

For further information, please contact:

Cannabics Pharmaceuticals, Inc.
+1-877-424-2429
info@Cannabics.com
http://www.Cannabics.com

Tags: advanced screeninganti-cancercancerCannabics PharmaceuticalscannabinoidCNBXpatientstherapeutic properties
Drew Hendricks

Drew Hendricks

Drew Hendricks is a business technology and social marketing specialist. Drew has also written for many major publishers such as Forbes, Entrepreneur Magazine and The Huffington Post. Drew has also worked with a variety of different startups around the globe as well as larger advertising agencies in the United States and the UK.

Related Posts

Zenabis returned $1.9 million worth of pot  to Sundial over bad quality and visible molds
Cannabis

Zenabis returned $1.9 million worth of pot to Sundial over bad quality and visible molds

August 22, 2019
269
Tilray to start exporting medicinal pot to Germany
Cannabis

Tilray to start exporting medicinal pot to Germany

August 21, 2019
134
CannTrust stocks fell another 5% after weed distributor returned millions worth of pot
Cannabis

CannTrust stocks fell another 5% after weed distributor returned millions worth of pot

August 20, 2019
147
Cannabis stocks fell as possible recession brews
Cannabis

Cannabis stocks fell as possible recession brews

August 14, 2019
157
Hexo’s Stocks Continue To Suffer A Cannabis Stocks Dive
Cannabis

Aurora Cannabis hovers trade flat amid strong market

August 13, 2019
161
Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%
Cannabis

Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%

August 12, 2019
128
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.